Descripción general
Select a topic to solve related cases or follow a course topic
-
Topic 1Long COVID
-
Topic 2New hope for patients progressing after prior treatment for mUCa
-
Topic 3Immunotherapy and antibody-drug conjugates: handling AEs and special populations
-
Topic 4First-line therapy of synchronous and metachronous metastatic UCa
-
Topic 5Histological subtypes of (N)MIBC: managed differently compared to pure UCa?
-
Topic 6Adjuvant treatment approaches for MIBC
-
Topic 7COVID-19 vaccines
-
Topic 8Treatment of acute COVID-19
-
Topic 9Acute COVID-19 in special populations
-
Topic 10Biochemical recurrence after radical prostatectomy
-
Topic 11Tratamiento inicial del dolor debido a artrosis
-
Topic 12Artrosis: ¿qué opciones se deben plantear después del fracaso del tratamiento?
-
Topic 13Tratamiento del dolor asociado a la artrosis en pacientes con enfermedades concomitantes
-
Topic 14Derivación y seguimiento del dolor crónico asociado a la artrosis
-
Topic 15High-risk non-metastatic prostate cancer
-
Topic 16Tailoring treatment for metastatic hormone-sensitive prostate cancer
-
Topic 17Finding the right ADT for the right patient
-
Topic 18Follow-up surveillance regimes to consider for (very) high-risk NMIBC and MIBC
-
Topic 19High-risk non-metastatic prostate cancer: the devil is in the details
-
Topic 20CRPC: treatment in daily clinical practice
-
Topic 21mCRPC: novel and emerging agents
-
Topic 22Treatment of low and intermediate-risk PCa
-
Topic 23Active surveillance: yes or no?
-
Topic 24Adverse pathology at radical prostatectomy
-
Topic 25Finding the right ADT for the right patient
-
Topic 26Tailoring treatment for metastatic hormone-sensitive prostate cancer
-
Topic 27Management of non-neurogenic female OAB
-
Topic 28Initial management of nocturia
-
Topic 29Male LUTS: keep on learning
-
Topic 30Initial treatment of MIBC
-
Topic 31Follow-up surveillance regimes for low-/intermediate-risk NMIBC
-
Topic 32Low- and intermediate-risk NMIBC: surveillance or intravesical therapy?
-
Topic 33UPDATED --- Systemic therapy for HER2-positive early breast cancer
-
Topic 34First-line systemic therapy in metastatic renal cell carcinoma
-
Topic 35Systemic therapy for mRCC: second line and beyond
-
Topic 36UPDATED --- Adjuvant systemic treatment of luminal A/B early breast cancer in premenopausal women
-
Topic 37Management of small renal masses
-
Topic 38UPDATED --- Adjuvant systemic treatment of luminal A/B early breast cancer in postmenopausal women
-
Topic 39NEW --- Systemic therapy for early stage TNBC
-
Topic 40Local therapy for mRCC
-
Topic 41UPDATED --- Radiotherapy for early breast cancer
-
Topic 42Management of HER2+ MBC
-
Topic 43Brain metastases in patients with HER2+ breast cancer
-
Topic 44CDK4/6 inhibitors for everyone? Treatment strategies in HR+ HER2- advanced breast cancer
-
Topic 45Theragnostic testing – choosing the right therapy in mTNBC
-
Topic 46Challenges in high-risk NMIBC